EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington’s Disease

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington’s Disease

Publication date: Jul 10, 2019

CAMBRIDGE, Massachusetts, July 9, 2019 /PRNewswire/ — EIP Pharma, Inc. , a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for the cognitive dysfunction associated with Huntington’s disease, a rare, genetically inherited disease that causes the nerve cells of the brain to progressively degenerate.

The primary objective of the study is to determine whether neflamapimod, a brain-penetrant, oral small molecule that inhibits the enzyme p38 alpha, can reverse the hippocampal synaptic dysfunction associated with early Huntington’s disease.

“We believe that neflamapimod has the potential to treat cognitive impairments associated with Huntington’s disease and can therefore benefit patients early in the course of their disease.

Recently, impairment in hippocampus-dependent cognitive function was defined as one of the earliest clinical manifestations of Huntington’s disease.

This Phase 2 proof-of-concept study is a double-blind, placebo-controlled, two-period, 10-week treatment, within-subject, crossover study of neflamapimod in early-stage Huntington’s disease (HD), with a washout period of eight to 12 weeks between the two treatment periods.

Concepts Keywords
Alzheimer Alzheimer’s disease
Autosomal Dominant Alpha
Brain Hippocampus
Cambridge Neuron
CAMBRIDGE Intensive care medicine
CEO Delirium
Chorea Dementia
Cognitive RTT
Cognitive Dysfunction Branches of biology
Cross Medical specialties
Crossover Psychiatric diagnosis
Double Blind Cognitive disorders
Enzyme Medicine
Gene Chorea
Hippocampal Benefit early disease
Hippocampus Inflammation
Huntington Movement disorder
Inflammation
MA
Massachusetts
Maze
Movement Disorder
Nerve
Neurodegenerative Diseases
Neurons
P38
P38 MAP Kinase
Penetrant
Period 10
Pipeline
Placebo
Small Molecule
Spatial Learning
Stress
Synaptic
Toxicity
Virtual Water
Washout

Semantics

Type Source Name
drug DRUGBANK Water
disease MESH multiple
disease MESH movement disorder
disease MESH CNS diseases
disease MESH development
gene UNIPROT CRK
gene UNIPROT MAPK1
gene UNIPROT AHSA1
gene UNIPROT GRAP2
gene UNIPROT POLDIP2
gene UNIPROT MAPK14
gene UNIPROT AIMP2
disease MESH cognitive dysfunction
drug DRUGBANK Neflamapimod
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Coenzyme M
pathway BSID Neurodegenerative Diseases
gene UNIPROT SGSM3
disease MESH inflammation
disease MESH neurodegenerative diseases

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *